{"id":45,"date":"2022-10-10T15:06:42","date_gmt":"2022-10-10T06:06:42","guid":{"rendered":"https:\/\/cytopathfinder.com\/cp-bin\/en\/?page_id=45"},"modified":"2023-02-21T13:47:00","modified_gmt":"2023-02-21T04:47:00","slug":"company","status":"publish","type":"page","link":"https:\/\/cytopathfinder.com\/eng\/company\/","title":{"rendered":"COMPANY"},"content":{"rendered":"
\n

Our Vision<\/h2>\n

Contributing to people’s health based on Science and Innovation
\nSince 2004, we have been working with pharmaceutical companies and academia to analyze the functions of genes in various cells that form the basis of the human body and mechanism by which proteins are expressed.
\nThe development of new drugs and therapeutics requires a long development period and high R&D costs. In cellular research, the basic research stage, we aim to contribute to leaps forward in new drug discovery by providing more reliable and efficient technologies and services.
\nInnovation and improvement in life sciences are rapid, but are supported by strenuous research efforts.
\nBased on our accumulated core technology, we will develop applications and supply products and services leading to the improvement of medical world and meeting customer\u2019s needs.
\nTo that end, we will continue to develop and improve our technology.
\nWe will strive to establish a sustainable business so that we can realize our objectives.<\/p>\n<\/section>\n

<\/p>\n

\n

Message from CEO<\/h2>\n

I am Ryuji Yamamoto , CEO of CytoPathfinder, Inc.
\nWhile I did not have previous experience in life sciences, in 2010, by request of government officials, I started to support CytoPathfinder, a bio-venture with unique technology, spun out from the National Insitute.
\nUtilizing my long experience establishing and managing small and medium size enterprises, together with our staff,we will focus on only one product type worldwide.
\nSmall but having a big dream, we are aiming, together with business partners globally, to solve customers\u2019 problems and meet their expectations.<\/p>\n

Ryuji Yamamoto
\nCEO,CytoPathfinder,Inc.<\/p>\n<\/section>\n

<\/p>\n

\n

Business<\/h2>\n

Transfection experiments are important tools in in vitro high-throughput loss-of-function assays in drug discovery and medical research, and are conducted in academic research institutes and pharmaceutical companies worldwide.
\nThe transfection experiments themselves are conventionally conducted in the liquid phase.
\nIn our solid-phase method, various nucleic acids, transfection reagents and our patented accelerator are dried as a non-covalently bound complex on the bottom surface of SBS standard micro plates.
\nWe are providing these solid-phase transfection plates to customers.
\nThis allows customers to simply add cells and apply their existing liquid handling & assay system no additional systems are required.
\nWe are ready to consult with customers at both the planning and data analysis stages of their experiments.
\nWe have been providing high density multi-well palates (1536,384,96 well) for high \u2013throughput screening.
\nIn addition, we are developing large volume solid -phase cell culture plate to support cell therapy approaches.<\/p>\n

Company Information<\/h2>\n<\/section>\n

<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
Company Name<\/td>\nCytoPathfinder, Inc.<\/td>\n<\/tr>\n
Established<\/td>\nDecember 20, 2004<\/td>\n<\/tr>\n
Capital<\/td>\nJPY 17.65 Million<\/td>\n<\/tr>\n
End of Fiscal Year<\/td>\nNovember<\/td>\n<\/tr>\n
Management Team<\/td>\n\u00b7 Ryuji Yamamoto(CEO)
\n\u00b7 Alun McCarthy, Ph.D. (CSO)
\n\u00b7 Keiji Mitani<\/td>\n<\/tr>\n
Auditors<\/td>\n\u00b7 Masayoshi Ishikawa<\/td>\n<\/tr>\n
Address<\/td>\n[Head Office]<\/p>\n

Office Square Building Shinjuku 501, 3-11-20 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan<\/p>\n

[Innovation Center]<\/p>\n

Second Taiko Building 3-C, 3-11-16 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan<\/td>\n<\/tr>\n

Phone<\/td>\n[Head Office]<\/p>\n

+81-3-6383-4008<\/p>\n

[Innovation Center]<\/p>\n

+81-3-5530-8086<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n


\n
\n<\/p>\n

\n

History<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Dec. 2004<\/td>\nEstablished as spin \u2013out venture company of the National Institute of Science and Technology (AIST)<\/td>\n<\/tr>\n
2008<\/td>\nLicensed out of our siRNA solid \u2013phase transfection technology to Takeda Pharmaceutical; (in-company use)<\/td>\n<\/tr>\n
2009<\/td>\nCytoPathfinder acquired PGIS Ltd. and its wholly-owned UK subsidiary PGXIS Ltd., a pharmacogenomic specialist company.<\/td>\n<\/tr>\n
2010<\/td>\nFANCL unveils a High Performance Anti-aging Cosmetic Material Co-developed with CytoPathfinder<\/td>\n<\/tr>\n
Mar. 2011<\/td>\nShareholders and Management team was reorganized, with Mr. Ryuji Yamamoto inducted as President, CEO<\/td>\n<\/tr>\n
2015<\/td>\nAll intangible assets of PGXIS, UK acquired by C4X Discovery Ltd, UK, and PGXIS became a sleeping company.<\/td>\n<\/tr>\n
2019<\/td>\nWe have started joint work with PhoenixBio Co., Ltd. concerning in vitro siRNA transfection assay kits for human hepatocyteo cells from PXB mice<\/td>\n<\/tr>\n
2021<\/td>\nCytoPathfider Innovation Center moved from AIST Rinkai to Nishi-Shinjuku<\/td>\n<\/tr>\n
2021<\/td>\nSuccessful crowd-funding using FUNDINNO.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Government subsidy projects<\/h3>\n\n\n\n\n\n\n
2009-2011<\/td>\nNEDO* grants subsidy to CytoPathfinder for the development of a Cellular Pharmacogenomics (PGx) system for profiling hepatotoxic compounds. (*New Energy and Industrial Technology Development Organization)<\/td>\n<\/tr>\n
2011-2014<\/td>\nCytoPathfinder was a grant recipient in two global technology collaboration support programs for FY2013
\n“Prototyping and global dissemination of a human iPS cell production plate kit”<\/td>\n<\/tr>\n
2013-2014<\/td>\n“Prototyping and overseas sales channel development of a tool kit for supporting human miRNA functional analytical research”<\/td>\n<\/tr>\n
May 2022<\/td>\nCytoPathfinder grant recipient “Development of large \u2013volume gene edited cell culture plate using
\nsolid-phase transfection technology”<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Cooperative research with Academia<\/h3>\n\n\n\n\n\n\n\n\n\n
2010-.<\/td>\nCytoPathfinder begins collaboration with AIST on Cellular PGx. and solid \u2013phase transfection of Plasmid DNA<\/td>\n<\/tr>\n
2014<\/td>\nStudy of hepatitis B onset mechanism by Hiroshima University, CytoPathfinder supplied whole-genome solid-phase screening plates<\/td>\n<\/tr>\n
2014<\/td>\nThe Institute of Medical Science, University of Tokyo: Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. We supplied siRNA solid \u2013phase transfection screening plates.<\/td>\n<\/tr>\n
2014<\/td>\nOxford University\/ Karolinska Institute Whole \u2013genome siRNAs screening, double knockdown experiment for anti-cancer drug development targeting DNA repair mechanism.<\/td>\n<\/tr>\n
2014-.<\/td>\nNational Institute of Health Science : Whole genome siRNA screening for the analysis of antisense nucleic acid uptake mechanism<\/td>\n<\/tr>\n
2014-.<\/td>\nTohoku University, Graduate school of Medicine: Development of ER+ Breast cancer Subtype Classification using clinical samples.
\nWe supplied Plasmid DNA solid-phase transfection plate (non viral method was needed)<\/td>\n<\/tr>\n
Aug 2020<\/td>\nCo- research with AIST “Study of assay system and gene analysis using mouse multipotent stem cell
\nby using solid \u2013phase transfection plates<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n","protected":false},"excerpt":{"rendered":"Our Vision Contributing to people’s health based on Science and Innovation Since 2004, we have been work […]","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-45","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/pages\/45","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/comments?post=45"}],"version-history":[{"count":36,"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/pages\/45\/revisions"}],"predecessor-version":[{"id":331,"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/pages\/45\/revisions\/331"}],"wp:attachment":[{"href":"https:\/\/cytopathfinder.com\/eng\/wp-json\/wp\/v2\/media?parent=45"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}